CLINICAL AND SUBCLINICAL CHARACTERISTICS OF PATIENTS WITH ADVANCED OR METASTATIC PANCREATIC CANCER AT K HOSPITAL

Thanh Đức Lê1,, Thành Lập Bùi 2
1 National cancer hospital
2 Hanoi medical university

Main Article Content

Abstract

Objectives: Clinical and subclinical characteristics of patients with advanced and metastatic pancreatic cancer at K hospital. Patients and methods: Retrospective descriptive study of 170 patients were diagnosed locally advanced or metastatic pancreatic adenocarcinoma at K hospital. Results: The mean age was 49.2 years. The male/female ratio was 1.3/1. The proportion of patients with a history of smoking, alcohol, and diabetes were 42.4%, 44.1%, and 25.9%, respectively. Patients admitted to the hospital mainly because of abdominal pain accounted for 80.0%. There were 88 (51.8%) patients with pancreatic head cancer, 82 (48.2%) patients with tumors in the tail and body of the pancreas. Pancreatic ductal adenocarcinoma accounted for the majority (86.4%), other types accounted for a low percentage (13.6%). The rate of abdominal lymph nodes was 62.4%, of which 75(44.1%) patients had N1 nodes and 31(18.2%) patients had N2 nodes. The rate of tumor stage T2, T3 and T4 were 15.9%, 31.8% and 52.4%, respectively. Patients with distant metastases accounted for 62.9%. At the time of diagnosis, 78.7% of patients had elevated CA19.9 levels, 44.7% of patients had elevated CEA levels. In which 42.1% of patients had CA19.9 increased over 500 U/mL. Conclusion: Advanced or metastatic pancreatic cancer has a high rate of liver and peritoneal metastases, while lung and bone metastases are less common.

Article Details

References

1. Nguyễn Bá Đức, Trần Văn Thuấn, Nguyễn Tuyết Mai (2010). Ung thư tụy. Điều trị nội khoa bệnh ung thư. Nhà xuất bản Y học, 189 - 199
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. doi:10.3322/caac.21660
3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Pancreatic cancer in Viet Nam.CA Cancer J Clin. 2021.
4. Genkinger J.M., Spiegelman D., Anderson K.E. và cộng sự. (2009). ALCOHOL INTAKE AND PANCREATIC CANCER RISK: A POOLED ANALYSIS OF FOURTEEN COHORT STUDIES. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, 18(3), 765–776.
5. Nguyễn Trường Sơn. Nghiên cứu giá trị siêu âm nội soi và chọc hút bằng kim nhỏ trong chẩn đoán ung thư tụy. Luận án tiến sỹ. Đại học Y Hà Nội.2014
6. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. J Clin Oncol. 2005;23(15):3509-3516.
7. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011; 364(19):1817-1825. doi:10.1056/NEJMoa1011923
8. Von Hoff DD, Ervin T, Arena FP, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369(18):1691-1703..
9. Đặng Thị Vân Anh. Nhận xét đặc điểm lâm sàng, cận lâm sàng và kết quả hóa trị trên bệnh nhân ung thư tụy tại bệnh viện K. Luận văn Bác sỹ nội trú. Đại học Y Hà Nội.2012.
10. Wang Y, Xiao X, Wang T, et al. A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma. J Cancer. 2018; 9(7):1301-1307. doi:10.7150/jca.23984